BAUSCH HEALTH AMERICAS, INC.
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT02462122
- Locations
- 🇺🇸
Valeant Site 13, Detroit, Michigan, United States
🇺🇸Valeant Site 3, Portland, Oregon, United States
🇺🇸Valeant Site 15, Houston, Texas, United States
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1054
- Registration Number
- NCT02387359
- Locations
- 🇺🇸
Synergy Research Site, Wauwatosa, Wisconsin, United States
🇺🇸Synergy Research Site., Nashville, Tennessee, United States
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02240121
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02240108
A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT02173392
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02129751
- Locations
- 🇺🇸
Valeant, Bridgewater, New Jersey, United States
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
- Conditions
- Interventions
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1410
- Registration Number
- NCT02122471
- Locations
- 🇺🇸
Synergy Research Site, Richland, Washington, United States
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02047604
- Locations
- 🇺🇸
Santarus Clinical Investigational Site 1012, Phoenix, Arizona, United States
🇺🇸Santarus Clinical Investigational Site 1004, El Cajon, California, United States
🇺🇸Santarus Clinical Investigational Site 1011, San Leandro, California, United States
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT02045277
- Locations
- 🇺🇸
Valeant Site 13, Encino, California, United States
🇺🇸Valeant Site 15, Santa Rosa, California, United States
🇺🇸Valeant Site 11, San Diego, California, United States
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT02029495
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom